Lyra Therapeutics (LYRA) director surrenders 640 shares to issuer

Rhea-AI Filing Summary

Lyra Therapeutics director W. Bradford Smith reported a disposition of common stock back to the company. On this Form 4, he returned 640 shares to the issuer in a transaction coded as a disposition to issuer at a reported price of $0.00 per share, leaving him with no directly held shares afterward.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Smith W Bradford

Role null

Type	Security	Shares	Price	Value
Disposition	Common Stock	640	$0.00	--

Holdings After Transaction: Common Stock — 0 shares (Direct, null)

Footnotes (1)

Key Figures

Shares disposed: 640 shares Transaction price: $0.00 per share Shares after transaction: 0 shares +1 more

4 metrics

Shares disposed 640 shares Non-derivative disposition to issuer

Transaction price $0.00 per share Reported for disposition to issuer

Shares after transaction 0 shares Total direct holdings following transaction

Dispose transactions 1 transaction Transaction summary disposeCount

Key Terms

Disposition to issuer, Common Stock, Form 4

3 terms

Disposition to issuer financial

"The transaction is coded as a disposition to issuer"

Common Stock financial

"The Form 4 reports 640 shares of Lyra Therapeutics common stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"The Form 4 reports that director W. Bradford Smith disposed of 640 shares"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith W Bradford

(Last) (First) (Middle)

C/O LYRA THERAPEUTICS, INC.

480 ARSENAL WAY

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lyra Therapeutics, Inc. [ LYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		D		640	D	$0	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Jason Cavalier, Attorney-in-Fact for W. Bradford Smith	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Lyra Therapeutics (LYRA) report on this Form 4?

The Form 4 reports that director W. Bradford Smith disposed of 640 shares of Lyra Therapeutics common stock. The transaction is coded as a disposition to the issuer, meaning the shares were returned to the company rather than sold on the open market.

How many Lyra Therapeutics (LYRA) shares did the director dispose of?

The director disposed of 640 shares of Lyra Therapeutics common stock. This quantity is specifically disclosed in the Form 4 transaction table for a non-derivative disposition to the issuer, identified by transaction code D for disposition.

What does a 'disposition to issuer' mean for Lyra Therapeutics (LYRA) stock?

A disposition to issuer indicates shares were transferred back to Lyra Therapeutics rather than sold in the market. In this Form 4, 640 common shares were returned to the company, with a reported per-share transaction price of $0.00.

What are the director’s Lyra Therapeutics (LYRA) holdings after this transaction?

After the reported disposition, the director’s direct holdings are shown as zero shares. The Form 4 table lists total shares following the transaction as 0.0000 for this non-derivative position, indicating no remaining directly held common stock.

Was this Lyra Therapeutics (LYRA) insider transaction a market sale or purchase?

The transaction is not an open-market sale or purchase. It is coded as a disposition to the issuer, meaning 640 shares of common stock were transferred back to Lyra Therapeutics at a reported price of $0.00 per share.